Class / Patent application number | Description | Number of patent applications / Date published |
536600400 | Daunomycin or derivative | 15 |
20090099346 | THERMALLY STABLE CRYSTALLINE EPIRUBICIN HYDROCHLORIDE - A crystalline form of epirubicin hydrochloride, named herein as “type II” crystalline epirubicin hydrochloride, has excellent thermal stability. Type II crystalline epirubicin hydrochloride has a powder X-ray diffraction pattern having average values of diffraction angle (2θ) and relative intensity P(%) as presented in the following table: | 04-16-2009 |
20090176974 | METHOD OF ARALKYLATION OF 4'-HYDROXYL GROUP OF ANTHRACYLINS - A method for the aralkylation of anthracyclins by utilizing an aralkylating agent R | 07-09-2009 |
20090203889 | Bivalent linkers and conjugates thereof - Bivalent linkers derived from compounds of formulae (V), (VI), and (VII), where X | 08-13-2009 |
20120130059 | ANTHRACYCLINE DERIVATIVE CONJUGATES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR COMPOUNDS - The present invention relates to conjugates of therapeutically useful anthracyclines with carriers such as polyclonal and monoclonal antibodies, proteins or peptides of natural or synthetic origin; methods for their preparation, pharmaceutical composition containing them and use thereof in treating certain mammalian tumors. | 05-24-2012 |
20120142906 | PROCESS FOR THE PREPARATION OF MORPHOLINYL ANTHRACYCLINE DERIVATIVES - The present invention provides a process for the preparation of a morpholinyl anthracycline derivative in good yields and purity, including 3′-deamino-3″-4′-anhydro-[2″(S)-methoxy-3″(R)-hydroxy-4″-morpholinyl]doxorubicin (1). | 06-07-2012 |
20120277415 | METHOD OF PRODUCING 4-DEMETHOXYDAUNORUBICIN - The present invention relates to a method for the synthesis of 4-demethoxydaunorubicin (idarubicin) having the chemical structure of formula (I), which involves the demethylation of 3′-Prot-daunorubicin in the presence of a soft Lewis acid. The method of the present invention does not comprise cleavage of the glycosidic linkage at carbon C7, thus resulting in a faster synthesis cycle and an improved yield of the final product. | 11-01-2012 |
20130116416 | KETOREDUCTASE MUTANT - Disclosed are a ketoreductase mutant which can be used for an efficient production of daunorubicin derivatives, a DNA encoding the mutant, a transformant prepared by introducing the DNA thereinto to produce a daunorubicin derivative, and a process of producing a daunorubicin derivative using the transformant. The ketoreductase mutant has an amino acid sequence in which one amino acid residue or two or more amino acid residues selected from the group consisting of amino acids located at positions corresponding to the 42nd, 149th, 153rd, 270th, and 306th amino acids in the amino acid sequence of a ketoreductase (EvaE) from a chlororemomycin-producing bacterium ( | 05-09-2013 |
20140148587 | CRYSTALLINE 4'-EPIDAUNORUBICIN HYDROCHLORIDE AND USE THEREOF - 4′-epidaunorubicin hydrochloride is provided in a crystalline form which is stable and readily soluble. A process of producing the crystalline form includes crystallizing 4′-epidaunorubicin hydrochloride in a solvent system including (a) solvent A selected from C | 05-29-2014 |
20140171629 | MEDICINAL AGENT FOR MEDICAL APPLICATIONS - Provided is a medicinal agent for medical applications, which can act on the function of a target cell specifically. The medicinal agent for medical applications comprises: a cell-incorporated substance that can be incorporated into a target cell specifically; and an acting substance that can act on the function of the target cell and is bound to the cell-incorporated substance. | 06-19-2014 |
20140343261 | SORBENT COMPRISING ON ITS SURFACE AN ALIPHATIC UNIT HAVING AN ANIONIC OR DEPROTONIZABLE GROUP FOR THE PURIFICATION OF ORGANIC MOLECULES - The present invention relates to a sorbent comprising a solid support material, the surface of which comprises a residue of a general formula (I), wherein the residue is attached via a covalent single bond to a functional group on the surface of either the bulk solid support material itself or of a polymer film on the surface of the solid support material. Furthermore, the present invention relates to the use of the sorbent according to the invention for the purification of organic molecules, in particular pharmaceutically active compounds, preferably in chromatographic application. | 11-20-2014 |
20140350230 | MULTI-FUNCTIONAL NUCLEIC ACID-BASED ANTI-CANCER DRUG CAPABLE OF TARGETING AND THERAPY, METHOD FOR PREPARING SAME AND ANTI-CANCER COMPOSITION COMPRISING SAME - The present invention relates to a multi-functional nucleic acid-based anti-cancer drug in which the anti-cancer drug is physically bound to a linear nucleic acid having a thiol group at 5′ terminal thereof and then gold nanoparticles and aptamers are chemically bound. The present invention also relates to a method for preparing the anti-cancer drug and to an anti-cancer composition comprising the anti-cancer drug. The multi-functional nucleic acid-based anti-cancer drug according to the present invention uses A10 aptamer to achieve high targeting properties, and uses high-concentration anti-cancer drugs and gold nanoparticles to enable dual therapy of thermal therapy/chemical therapy, and may have less side effects and be more effective in anti-cancer therapy compared to existing anti-cancer drugs. | 11-27-2014 |
20140357848 | CRYSTALLINE 4'-EPIDAUNORUBICIN HYDROCHLORIDE AND USE THEREOF - 4′-epidaunorubicin hydrochloride is provided in a crystalline form which is stable and readily soluble. A process of producing the crystalline form includes crystallizing 4′-epidaunorubicin hydrochloride in a solvent system including (a) solvent A selected from C | 12-04-2014 |
20140378673 | PRODRUG USING NITROIMIDAZOLE - Provided is a prodrug of 2-nitro-1-imidazolepropionic acid and a therapeutically active organic compound having on the molecule an amino group, a cyclic amino group or a hydroxyl group, particularly a prodrug in which the therapeutically active organic compound is selected from among antitumor agents. The prodrug cleaves specifically under hypoxic conditions in vivo to exhibit the inherent therapeutic activity. | 12-25-2014 |
20150299241 | METHOD FOR PREPARING HIGHLY PURE DOXORUBICIN - The present invention relates to a method for preparing highly pure doxorubicin. The method comprises the following steps: (1) chromatographing a prepurified doxorubicin solution by using macroporous resin, pre-washing the chromatographed system by using an acidic low concentration aqueous organic solvent, and performing elution by using an acidic high concentration aqueous organic solvent; (2) performing chromatographic separation on eluted components by using a preparative column, so that a highly pure doxorubicin component can be obtained, and the doxorubicin can, if needed, be separated from the aqueous solution by using conventional concentration and crystallization methods in the prior art. The present invention has the advantages such as simplicity, high yield, low cost, and less environmental pollution. The content of the prepared doxorubicin is greater than 99.5%, the content of each impurity is controlled to be lower than 0.10%, and the USP and EP standards are met. | 10-22-2015 |
20160137683 | Method for Preparing Epirubicin and Intermediate Thereof - The present invention provides a method for preparing epirubicin and an intermediate adaptive to the method. The preparation method may include: reacting tert-Butyldimethylsilyl chloride with N-trifluoroacetyl adriamycin to obtain a first compound N-trifluoroacetyl-14-O-tert-Butyldimethylsilyl adriamycin; oxidizing the first compound to obtain a second compound 4′-ketone-N-trifluoroacetyl-14-O-tert-Butyldimethylsilyladriamycin; reducing the second compound to obtain a third compound N-trifluoroacetyl-14-O-tert-Butyldimethylsilyl epirubicin; and performing deprotection and hydrolysis reactions on the third compound to obtain epirubicin. The method of the present invention needs low cost, fewer reaction steps, provides high yield and high product purity, and avoids serious pollution caused by a bromination reaction in a conventional method. | 05-19-2016 |